Precigen director Jeffrey Kindler sells $1.38m in stock
Precigen director Jeffrey Kindler sold 185,000 shares of the company's stock on August 26, 2026, for a total of $1.38 million. The sale occurred at prices between $7.38 and $7.59 per share, with an average price of $7.44. Kindler now owns 17,100 shares of Precigen common stock. The company's shares are currently trading at $6.95, near its 52-week high of $7.71, following a 83% increase over the past six months.
Analysts consider the stock to be undervalued, with a Fair Value of $7.46. Precigen's second-quarter results exceeded expectations, with earnings of $0.05 per share, surpassing the anticipated loss of $0.01. Revenue surged to $54.98 million, nearly double the projected $27.83 million, driven by strong demand for their therapy PAPZIMEOS for adult recurrent respiratory papillomatosis.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
